Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Sodium Glucose Co-transporter 2 Inhibitor (dapagliflozin) on Weight Loss in Non-diabetic Adults with Obesity: Triple-blinded, Randomized, Placebo-controlled Trial.

NCT06000462 is registered in ClinicalTrials.gov with Oman Ministry of Health as lead sponsor.

NCT NCT06000462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06000462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Sodium Glucose Co-transporter 2 Inhibitor (dapagliflozin) on Weight Loss in Non-diabetic Adults with Obesity: Triple-blinded, Randomized, Placebo-controlled Trial.
Lead sponsor
Oman Ministry of Health
Phase
Phase 4
Overall status
Active, not recruiting
Start date
April 22, 2024
Completion date
December 30, 2025
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dapagliflozin adverse reaction, effect of drug, obesity, weight loss